This clinical trial progression culminated in a recently completed phase III randomized study of cisRA together with ch14.18, IL-2, and GM-CSF vs. cisRA only for patients with high-risk neuroblastoma who had a clinical response to induction therapy and myeloablative consolidation therapy/AHSCT. The gene discussed is IL2; the disease is neuroblastoma.